Table 1.
Cohort characteristics
| State | Nr. | Sex a | Age (Mean +/sd) | Age Pval b | Panel 1–5 c | 42-Plex d | Panel 6–11 e | Ovarian Cancer Stages | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IV | ||||||||
| At Diagnosis | 77 | 1.0 | 58.8 (12.5) | 0.17 | 50 e | 77 | 77 | 10 | 3 | 40 | 24 |
| At Surgery 1st | 159 | 1.0 | 61.8 (11.9) | 0.17 | 159 | 100 | 35 | 9 | 96 | 19 | |
| At Surgery 2nd | 91 | 1.0 | 61.8 (12.6) | 0.38 | 79 | 35 | 7 | 33 | 4 | ||
| 47 | 11 | 36 | |||||||||
| Control | 50 | 1.0 | 58.4 (17.6) | 0.39 | 50 | ||||||
a Fraction of women in each cohort. b Lowest nominal p-value (two-sided Wilcoxon-text) for age-distribution in this cohort compared with any of the other cohorts. c Cardiovascular II, Cardiovascular III, Inflammation, Neurology and Oncology. This data is referred to as Data S1 in the Supplementary material, “At Diagnosis” and “At surgery 2” only. d 41 proteins from Panel 1–5 c plus Prolactin. This data is referred to as Data S2 in the Supplementary material. e Cardiometabolic, Cell Regulation, Development, Immune Response, Metabolism and Organ Damage [18] This data is referred to as Data S3 in the Supplementary material.